With an ongoing threat posed by circulating zoonotic strains, new strategies are required to 8 prepare for the next emergent coronavirus (CoV). Previously, groups had targeted conserved 9 coronavirus proteins as a strategy to generate live-attenuated vaccine strains against current 10 and future CoVs. With this in mind, we explored whether manipulation of CoV NSP16, a 11 conserved 2'O methyltransferase (MTase), could provide a broad attenuation platform against 12 future emergent strains. Using the SARS-CoV mouse model, a NSP16 mutant vaccine was 13 evaluated for protection from heterologous challenge, efficacy in the aging host, and potential 14 for reversion to pathogenesis. Despite some success, concerns for virulence in the aged and 15 potential for reversion makes targeting NSP16 alone an untenable approach. However, 16 combining a 2'O MTase mutation with a previously described CoV fidelity mutant produced a 17 vaccine strain capable of protection from heterologous virus challenge, efficacy in aged mice, 18 and no evidence for reversion. Together, the results indicate that targeting the CoV 2'O MTase 19 in parallel with other conserved attenuating mutations may provide a platform strategy for 20 rapidly generating live-attenuated coronavirus vaccines. 21 on July 7, 2018 by TUFTS UNIV LIBRARIES http://jvi.asm.org/ Downloaded from Significance 22
Introduction
2B spike virus in terms of disease. Weight loss data, viral lung titer, and hemorrhage score 138 indicated little to no disease in mice vaccinated with dNSP16 compared to mock vaccinated 139 mice ( Fig. 2A-C) . Importantly, while not equivalent to neutralization of wild-type SARS-CoV, 140 sera from dNSP16-vaccinated mice were able to effectively block the SHC014 chimeric virus, 141 likely contributing to protection following vaccination (Fig. 2D) . Together, the data indicate that a 142 live-attenuated NSP16 vaccine has sufficient capacity to protect from heterologous CoV 143 challenge in young mice.
144
Low dose dNSP16 vaccination provides protection to aged mice.
145
With high rates of mortality, aged populations represent a vulnerable group in need of effective 146 vaccines to coronaviruses (27) . However, previous work has shown that SARS-CoV vaccines 147 have had mixed success in aged populations (14, 28) . To explore efficacy of dNSP16 in a 148 senescent model, we examined infection of 12-month old BALB/c mice which recapitulates the 149 age-dependent susceptibility observed in humans. Following infection with 10 5 PFU of wild-type 150 or dNSP16, the 2'O MTase mutant was equal to WT SARS-CoV infection in terms of weight loss 151 and lethality ( Fig. 3A & B) . While this dose protected young mice from heterologous challenge, 152 significant pathogenesis occurred in the aged mice despite attenuation in viral replication at day 153 4 ( Fig. 3C) . Together, the data indicates that despite replication attenuation, the dNSP16 154 mutant harbors pathogenic potential at high doses in aged mice.
155
While capable of inducing lethal disease, the utilized dose of the dNSP16 mutant 156 represents a significant increase over the LD 50 of WT SARS-CoV in aged mice (29). Therefore,
157
we challenged 12-month old BALB/c mice with 100 PFU of WT or dNSP16 and evaluated 158 pathogenesis. Following low dose challenge, dNSP16 infected aged mice had reduced disease 159 as compared to control in terms of weight loss and survival ( Fig. 3D & E) . The reduced 160 pathogenesis corresponded to reduced viral replication at both days 2 and 4, recapitulating in 161 vivo attenuation previously observed in young animals ( Fig. 3F) (19) . Notably, dNSP16 infection 162 resulted in only marginal disease in terms of weight loss (<5%) and respiratory parameters, explore protection, 12-month old mice were vaccinated with 100 PFU of dNSP16 and 165 subsequently challenged 28 days later with a lethal dose of wild-type SARS-CoV MA15 (10 5 166 PFU). Both, in terms of weight loss and survival ( Fig. 4A & B) , vaccination with dNSP16 167 provided robust protection from lethal disease and pathogenesis; this protection corresponded 168 with the absence of detectable viral replication at both days 2 and 4 ( Fig. 4C) . Together, the 169 results indicate that while the dNSP16 mutant harbors some risk of pathogenicity at high doses, 170 it can also provide aged mice with robust protection from lethal challenge.
171
NSP16 mutant reverts in immune-compromised model.
172
Despite some important caveats, the dNSP16 mutant has demonstrated efficacy as a vaccine 173 following both, heterologous challenge and in aged models of SARS-CoV disease. However, 174 reversion and adaptation of a live attenuated strain represents a significant concern for its use in virulence including weight loss and lethality ( Fig. 5A & 5B) . Importantly, we examined the input 184 inoculum and found that the three samples that had no weight loss also had no detectable virus 185 suggesting clearance of the dNSP16 in these animals ( Fig. 5C ). With this in mind, the input 186 virus samples were amplified on Vero cells and the RNA sequence of NSP16 was examined for 187 reversion. Surprisingly, the results found that all five virus positive samples retained the two 188 nucleotide change producing the D130A mutation in NSP16 and suggested that virulence was coding changes outside of the D130A mutation in NSP16 ( Table 1) 
204
With this in mind, we set forth to evaluate a SARS-CoV mutant lacking both NSP16 activity as 205 well as CoV fidelity (dNSP16/ExoN). Compared to WT or the original dNSP16 mutant, the 206 SARS dNSP16/ExoN virus had replication deficit in its initial stock titers as well as in a multistep 207 growth curve ( Fig. 6A) ; however, the double mutant had equivalent replication to the SARS 208 ExoN mutant indicating the inclusion of the NSP16 mutation produced no additional replication 209 attenuation in vitro. In vivo, the SARS dNSP16/ExoN mutant also had significant attenuation 210 relative to WT control virus. We next infected 10-week old BALB/c with 10 4 PFU of either 211 dNSP16/ExoN or WT SARS-CoV MA15, lowering the dose due to reduced titer in the viral 212 stocks. Similar to the ExoN mutant (16), the dNSP16/ExoN mutant produced no weight loss with 213 significant changes compared to WT infection as early as day 2 post infection ( Fig. 6B ).
214
Similarly, viral replication was significantly attenuated at both days 2 and 4 ( Fig. 6C) . Finally, no Together, the data is consistent with the level of attenuation observed for the original SARS-
217
CoV ExoN mutant and suggested that the dNSP16/ExoN mutant may serve as a possible live 218 attenuated vaccine.
219
With vaccination in mind, we explored the dNSP16/ExoN mutant in the context of (Fig. 6F) . In addition, 227 hemorrhage scores indicated limited disease following vaccination with dNSP16/ExoN as 228 compared to control (Fig. 6G) . Importantly, sera from dNSP16/ExoN vaccinated mice was 229 capable of neutralizing both WT SARS-CoV as well as chimeric spike virus ( Fig. 6H) . While not 230 equivalent to neutralization induced by the dNSP16 mutant (Fig. 2) , the results indicate that the 231 double mutant vaccine provided robust protection from both homologous and heterologous 232 challenge.
233
Double mutant protects aged mice from lethal disease.
234
Having demonstrated efficacy in young mice and against heterologous challenge, we next
Discussion

272
The threat of zoonotic coronaviruses stems not only from their potential for emergence, 273 but also from the lack of effective strategies to combat epidemic coronavirus disease. While 
291
the absence of replication defects for NSP16 mutants offers both utility and risk. While capable 292 of inducing robust immunity, even to heterologous challenge, the NSP16 mutant virus retains 293 virulence in aged animals at high doses. Importantly, the augmented replication potentially 294 contributes to its ability to revert to virulence in immunocompromised models. Together, the 295 results suggest that the robust immunity induced by NSP16 mutants in young mice comes at the 296 on July 7, 2018 by TUFTS UNIV LIBRARIES http://jvi.asm.org/ Downloaded from cost of higher virulence and the potential for reversion, thus limiting its use to only dire 297 situations.
298
Given the risk associated with NSP16 mutation as a single target attenuation platform,
299
we evaluated ways to increase safety without sacrificing vaccine efficacy. We first considered 300 further targeting the other conserved residues within the KDKE motif, critical to 2'O MTase 
326
In pursuing vaccine platforms for coronaviruses, our data argues a multiple-mechanism, 327 attenuation approach may be the fastest route to an effective, safe vaccine in the context of an 
